help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Slovik, D. M.
Right arrow Articles by Lian, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slovik, D. M.
Right arrow Articles by Lian, J. B.

Journal of Clinical Endocrinology & Metabolism, Vol 59, 228-230, Copyright © 1984 by Endocrine Society

ARTICLES

Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting

DM Slovik, CM Gundberg, RM Neer and JB Lian

Serum levels of osteocalcin, the major noncollagenous bone protein, are elevated in patients with certain metabolic bone diseases, but the effects of other illnesses on serum osteocalcin levels are not known. We measured serum osteocalcin concentrations in 250 patients in a rehabilitation hospital who suffered from various illnesses. Mean serum osteocalcin levels were elevated in patients with 1) recent hip fracture who required open reduction and pin insertion (mean +/- SE, 19.0 +/- 3.2 ng/ml), 2) primary (22.0 +/- 4.9 ng/ml) or secondary hyperparathyroidism (51.6 +/- 9.9 ng/ml), 3) Paget's disease of bone (22.7 +/- 6.1 ng/ml), or 4) metastatic skeletal disease who had not received therapy (37.5 +/- 11.3). Mean serum osteocalcin levels were normal in patients who had received 1) a hip prosthesis for a recent fracture or for severe degenerative joint disease of the hip (6.4 +/- 0.9 ng/ml), 2) recent chemotherapy or irradiation for bone metastases (6.1 +/- 1.3 ng/ml), or 3) a variety of medical problems not related to bone disease (5.2 +/- 0.3 ng/ml). Serum osteocalcin and alkaline phosphatase values did not correlate. This study demonstrates that serum osteocalcin levels are normal in disorders not involving bone, can be used in a general-hospital setting, where concomitant illnesses are present, and may provide additional information for the clinical evaluation of metabolic bone disease.


This article has been cited by other articles:


Home page
 Ann. N. Y. Acad. Sci.Home page
J. S KINNEY, C. A RAMSEIER, and W. V GIANNOBILE
Oral Fluid-Based Biomarkers of Alveolar Bone Loss in Periodontitis
Ann. N.Y. Acad. Sci., March 1, 2007; 1098(1): 230 - 251.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Fohr, C. R. Dunstan, and M. J. Seibel
Markers of Bone Remodeling in Metastatic Bone Disease
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. F. Backeljauw and L. E. Underwood
Therapy for 6.5-7.5 Years with Recombinant Insulin-Like Growth Factor I in Children with Growth Hormone Insensitivity Syndrome: A Clinical Research Center Study
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1504 - 1510.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society